This information was provided by prnewswire
Send your Press Release here.
TORONTO, Nov. 12, 2018 /CNW/ – Beleave Inc. (CSE: BE) (OTCQX: BLEVF) (“Beleave” or the “Company“) is pleased to announce that it has secured genetics acquisition agreements for a broad range of cannabis seed varieties from diverse lineages.
There will be a total of 90 new varieties introduced in the coming year that have been selected to cover the entire spectrum of low, intermediate, and high THC and CBD profiles. The list includes well-known classic Sativa and Indica varieties with applications for both medical and adult recreational markets. Also included in the selection are a number of novel strains, not previously available in the Canadian market, which have been bred for select terpene profiles to offer distinct custom flavours and aromas.
Last week, Health Canada notified the Company that their existing license under the ACMPR had been updated for the new system reflecting the changes under the Cannabis Act.
In the coming months, Beleave will be completing construction and upgrades on new facilities in Ontario and British Columbia. Once completed, they will greatly increase the Company’s production capacity allowing Beleave to help supply the demands of Canada’s growing cannabis market.
“We are very happy with the new varieties being introduced and the potential they have for Beleave’s future. Our master grower has been working tirelessly to select and secure these strains,” said Beleave CEO, Andrew Wnek. “Our whole team has been working aggressively to bring us to this point. Whether it’s our increasing production capacity, expanded global distribution, or these new cannabis varieties; Beleave is ready.”
Leave a Reply